116 related articles for article (PubMed ID: 26763122)
1. Cylindromatosis--A Protective Molecule against Liver Diseases.
Hellerbrand C; Massoumi R
Med Res Rev; 2016 Mar; 36(2):342-59. PubMed ID: 26763122
[TBL] [Abstract][Full Text] [Related]
2. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R
Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553
[TBL] [Abstract][Full Text] [Related]
3. Cylindromatosis gene CYLD regulates hepatocyte growth factor expression in hepatic stellate cells through interaction with histone deacetylase 7.
Pannem RR; Dorn C; Hellerbrand C; Massoumi R
Hepatology; 2014 Sep; 60(3):1066-81. PubMed ID: 24811579
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of CYLD in human colon and hepatocellular carcinomas.
Hellerbrand C; Bumes E; Bataille F; Dietmaier W; Massoumi R; Bosserhoff AK
Carcinogenesis; 2007 Jan; 28(1):21-7. PubMed ID: 16774947
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer.
Nikolaou K; Tsagaratou A; Eftychi C; Kollias G; Mosialos G; Talianidis I
Cancer Cell; 2012 Jun; 21(6):738-50. PubMed ID: 22698400
[TBL] [Abstract][Full Text] [Related]
6. CYLD: a deubiquitination enzyme with multiple roles in cancer.
Massoumi R
Future Oncol; 2011 Feb; 7(2):285-97. PubMed ID: 21345146
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
8. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
Kovalenko A; Chable-Bessia C; Cantarella G; Israël A; Wallach D; Courtois G
Nature; 2003 Aug; 424(6950):801-5. PubMed ID: 12917691
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-specific disruption of recombination signal binding protein Jκ ameliorates hepatic fibrosis by attenuating inflammation through cylindromatosis in mice.
He F; Guo FC; Li Z; Yu HC; Ma PF; Zhao JL; Feng L; Li WN; Liu XW; Qin HY; Dou KF; Han H
Hepatology; 2015 Jan; 61(1):303-14. PubMed ID: 25145286
[TBL] [Abstract][Full Text] [Related]
10. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
11. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.
Urbanik T; Boger RJ; Longerich T; Becker K; Ehrenberg KR; Hövelmeyer N; Hahn M; Schuchmann M; Jäger D; Waisman A; Wörns MA; Schulze-Bergkamen H
J Hepatol; 2012 Nov; 57(5):995-1003. PubMed ID: 22728872
[TBL] [Abstract][Full Text] [Related]
12. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.
Trompouki E; Hatzivassiliou E; Tsichritzis T; Farmer H; Ashworth A; Mosialos G
Nature; 2003 Aug; 424(6950):793-6. PubMed ID: 12917689
[TBL] [Abstract][Full Text] [Related]
13. Blocking Notch signal in myeloid cells alleviates hepatic ischemia reperfusion injury by repressing the activation of NF-κB through CYLD.
Yu HC; Bai L; Yang ZX; Qin HY; Tao KS; Han H; Dou KF
Sci Rep; 2016 Sep; 6():32226. PubMed ID: 27680285
[TBL] [Abstract][Full Text] [Related]
14. Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control.
Massoumi R; Paus R
Bioessays; 2007 Dec; 29(12):1203-14. PubMed ID: 18008375
[TBL] [Abstract][Full Text] [Related]
15. Mutated cylindromatosis gene affects the functional state of dendritic cells.
Bros M; Dexheimer N; Besche V; Masri J; Trojandt S; Hövelmeyer N; Reissig S; Massoumi R; Grabbe S; Waisman A; Reske-Kunz AB
Eur J Immunol; 2010 Oct; 40(10):2848-57. PubMed ID: 20836156
[TBL] [Abstract][Full Text] [Related]
16. CYLD-mediated signaling and diseases.
Mathis BJ; Lai Y; Qu C; Janicki JS; Cui T
Curr Drug Targets; 2015; 16(4):284-94. PubMed ID: 25342597
[TBL] [Abstract][Full Text] [Related]
17. The tumor suppressor CYLD controls the function of murine regulatory T cells.
Reissig S; Hövelmeyer N; Weigmann B; Nikolaev A; Kalt B; Wunderlich TF; Hahn M; Neurath MF; Waisman A
J Immunol; 2012 Nov; 189(10):4770-6. PubMed ID: 23066153
[TBL] [Abstract][Full Text] [Related]
18. Cylindromatosis (CYLD) inhibits Streptococcus pneumonia-induced plasminogen activator inhibitor-1 expression via interacting with TRAF-6.
Wu J; Zhao J; Yu J; Zhang W; Huang Y
Biochem Biophys Res Commun; 2015 Aug; 463(4):942-7. PubMed ID: 26056944
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor CYLD regulates JNK-induced cell death in Drosophila.
Xue L; Igaki T; Kuranaga E; Kanda H; Miura M; Xu T
Dev Cell; 2007 Sep; 13(3):446-54. PubMed ID: 17765686
[TBL] [Abstract][Full Text] [Related]
20. Loss of CYLD might be associated with development of salivary gland tumors.
Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
